Abstract
With respect to the total cure failure of current drugs used in the treatment of neurodegenerative diseases, alternative strategies are followed. Particularly, neuroprotection approaches are questioned. Metal chelation, antioxidant towards oxidative stress, modulation of the amyloidogenic pathway, MAO-B inhibition, and NMDA receptor antagonism is more or less typical examples. Some of the representative drug candidates with promising neuroprotective features are assessed in clinical trials. Although initial attempts were found hopeful, none of the candidates have been found successful in each required clinical trials, particularly depending on the failures in terms of cognitive enhancement and slowing the progressive characteristics of neurodegenerative diseases. Today, neuroprotection is evaluated using multi-target ligand-based drug design studies. Within this study, the clinical outcomes of these studies, the rationale behind the design of the molecules are reviewed concomitant to the representative drug candidates of each group.
Keywords: Neurodegeneration, neuroprotection, amyloidogenic pathway, monoamine oxidase, iron chelator, antioxidant, cholinesterase, NMDA receptor, nitric oxide.
Current Pharmaceutical Design
Title:The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer’s Disease and Parkinson Disease
Volume: 26 Issue: 4
Author(s): Hayrettin O. Gülcan*Ilkay E. Orhan*
Affiliation:
- Eastern Mediterranean University, Faculty of Pharmacy, Famagusta, TR. North Cyprus, via Mersin 10,Turkey
- Gazi University, Faculty of Pharmacy, Department of Pharmacognosy, Etiler, Ankara,Turkey
Keywords: Neurodegeneration, neuroprotection, amyloidogenic pathway, monoamine oxidase, iron chelator, antioxidant, cholinesterase, NMDA receptor, nitric oxide.
Abstract: With respect to the total cure failure of current drugs used in the treatment of neurodegenerative diseases, alternative strategies are followed. Particularly, neuroprotection approaches are questioned. Metal chelation, antioxidant towards oxidative stress, modulation of the amyloidogenic pathway, MAO-B inhibition, and NMDA receptor antagonism is more or less typical examples. Some of the representative drug candidates with promising neuroprotective features are assessed in clinical trials. Although initial attempts were found hopeful, none of the candidates have been found successful in each required clinical trials, particularly depending on the failures in terms of cognitive enhancement and slowing the progressive characteristics of neurodegenerative diseases. Today, neuroprotection is evaluated using multi-target ligand-based drug design studies. Within this study, the clinical outcomes of these studies, the rationale behind the design of the molecules are reviewed concomitant to the representative drug candidates of each group.
Export Options
About this article
Cite this article as:
Gülcan O. Hayrettin *, Orhan E. Ilkay *, The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer’s Disease and Parkinson Disease, Current Pharmaceutical Design 2020; 26 (4) . https://dx.doi.org/10.2174/1381612826666200131103524
DOI https://dx.doi.org/10.2174/1381612826666200131103524 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research Synthesis and Biological Activities of Substituted Benzoxazepine: A Review
Mini-Reviews in Organic Chemistry Asthma Self-Management for School-Age Children
Current Pediatric Reviews Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design Segmentation of Ordinary Images and Medical Images with an Adaptive Hidden Markov Model and Viterbi Algorithm
Current Signal Transduction Therapy Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Current Drug Safety Meet Our Editorial Board Member
Current Medicinal Chemistry Reduced Alzheimer’s Disease Pathology by St. John’s Wort Treatment is Independent of Hyperforin and Facilitated by ABCC1 and Microglia Activation in Mice
Current Alzheimer Research An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Current Topics in Medicinal Chemistry Structure and Thermodynamics of Drug-RNA Aptamer Interactions
Mini-Reviews in Medicinal Chemistry Inhibition of Monoamine Neurotransmitter Transporters and Central Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review-Update
Current Medicinal Chemistry - Central Nervous System Agents Curcumin Exposure Modulates Multiple Pro-Apoptotic and Anti-Apoptotic Signaling Pathways to Antagonize Acetaminophen-Induced Toxicity
Current Neurovascular Research Interactions between Ketamine and Magnesium for the Treatment of Pain: Current State of the Art
CNS & Neurological Disorders - Drug Targets Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
Current Neuropharmacology An Optimal Approach for Selecting Discriminant Regions for the Diagnosis of Alzheimer's Disease
Current Alzheimer Research Research Progress of Essential Oil as a New Complementary Therapy in the Treatment of Depression
Mini-Reviews in Medicinal Chemistry Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Reversal of Metabolic and Neurological Symptoms of Phenylketonuric Mice Treated with a PAH Containing Helper-Dependent Adenoviral Vector
Current Gene Therapy Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function
Current Drug Metabolism